RGNX NASDAQ
REGENXBIO Inc.
1W: -10.8%
1M: -11.7%
3M: -31.4%
YTD: -51.4%
1Y: -49.4%
3Y: -59.2%
5Y: -81.0%
$6.60
+0.02 (+0.30%)
Weekly Expected Move ±8.5%
$6
$6
$7
$7
$8
Credit Risk of going bust: higher than 81% of companies Debt: 13.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.19 (down 97%), REGENXBIO Inc. would be worth roughly what it owes.
Total debt $69.0M against a stock market value of $435.7M.
Distance to default 2.51 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $34.5M (short-term plus half of long-term), stock volatility 96.3%; Altman Z'' -9.90. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.19 (down 97%), REGENXBIO Inc. would be worth roughly what it owes.
Total debt $69.0M against a stock market value of $435.7M.
Distance to default 2.51 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $34.5M (short-term plus half of long-term), stock volatility 96.3%; Altman Z'' -9.90. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
13 relationships12
As Filer
counterparties named
1
As Counterparty
mentioned by others
4
Rel. Types
2021-09-13
Earliest Filing
2025-08-07
Latest Filing
partner: 6
licensee: 4
investor: 1
supplier: 1
Counterparties (Filed by RGNX)
12 relationshipsCompanies named in RGNX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| AbbVie Global Enterprises Ltd. | ABBV | partner | Collaboration and license partner for sura-vec DR and wAMD programs | 2025-08-07 | View |
| AbbVie Inc. | ABBV | partner | Parent company of AbbVie Global Enterprises Ltd. | 2025-08-07 | View |
| Nippon Shinyaku | — | partner | Partner for RGX-121 and RGX-111 development programs | 2025-08-07 | View |
| Healthcare Royalty | — | investor | Counterparty in royalty monetization bond agreement | 2025-08-07 | View |
| Novartis Gene Therapies | NVSEF | supplier | Provider of Zolgensma platform technology | 2025-08-07 | View |
| Novartis Gene Therapies, Inc. | NVSEF | licensee | Licensor of Zolgensma® under an existing license agreement whose royalties collateralize the loan. | 2025-05-19 | View |
| Nippon Shinyaku Co., Ltd. | — | licensee | Licensor of clemidsogene lanparvovec (RGX-121) and RGX-111 under existing license agreements. | 2025-05-19 | View |
| Rocket Pharmaceuticals | — | licensee | Licensee of Company NAV® vectors under an existing license agreement. | 2025-05-19 | View |
| Ultragenyx Pharmaceuticals, Inc. | RARE | licensee | Licensee of Company NAV® vectors under an existing license agreement. | 2025-05-19 | View |
| Nippon Shinyaku Co., Ltd. | — | partner | Collaboration and License Agreement for development and commercialization of RGX-121 and RGX-111 | 2025-01-14 | View |
| AbbVie Global Enterprises Ltd. | ABBV | partner | Partner in Collaboration and License Agreement for RGX-314 development and commercialization | 2021-09-13 | View |
| AbbVie Inc. | ABBV | partner | Parent company of AbbVie Global Enterprises Ltd.; joint press release issuer | 2021-09-13 | View |
Mentioned As Counterparty
1 mentionsOther companies that named RGNX in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-16 | Officer/Director Change | View | |
| 2026-09-23 | Material Agreement | Agreement | View |
| 2026-08-25 | Officer/Director Change; Exhibits | View | |
| 2026-08-24 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-07-20 | Other Events; Exhibits | View | |
| 2026-06-29 | Other Events; Exhibits | View | |
| 2026-06-03 | Shareholder Vote; Other Events | View | |
| 2026-05-14 | Earnings Release; Regulation FD; Other Events; Exhibits | View | |
| 2026-03-20 | Material Agreement | Agreement | View |
| 2026-03-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-10 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2026-01-28 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-18 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-07 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Regulation | Agreement | View |
| 2025-06-03 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-19 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Regulation FD Dis | Agreement | View |
| 2025-05-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR